Immunovant’s muscle disorder treatment meets main goal in late-stage trial

(Reuters) -Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.

(Reporting by Christy Santhosh in Bengaluru; Editing by Maju Samuel)